Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant PDCD1 (Nivolumab Biosimilar) antibody

Reactivity: Human FACS, in vivo Host: Mouse Monoclonal 5C4-B8 unconjugated Recombinant Antibody
Catalog No. ABIN7200667
  • Target See all PDCD1 (Nivolumab Biosimilar) products
    PDCD1 (Nivolumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    Mouse
    Clonality
    • 1
    Monoclonal
    Conjugate
    • 1
    This PDCD1 (Nivolumab Biosimilar) antibody is un-conjugated
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Purpose
    Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody
    Specificity
    The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.
    Characteristics
    Recombinant Humanized IgG4 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Purity
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterility
    0.2 μm filtered
    Endotoxin Level
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.
    Clone
    5C4-B8
    Isotype
    IgG4 kappa
  • Application Notes
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Preservative
    Without preservative
    Handling Advice
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Expiry Date
    12 months
  • Target
    PDCD1 (Nivolumab Biosimilar)
    Abstract
    PDCD1 (Nivolumab Biosimilar) Products
    Synonyms
    CD279 antibody, PD-1 antibody, PD1 antibody, SLEB2 antibody, hPD-1 antibody, hPD-l antibody, programmed cell death 1 antibody, PDCD1 antibody
    Target Type
    Biosimilar
    Background
    What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab.

    PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).

    Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity.

    The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.
You are here:
Support